Isamu Sugiura

Isamu Sugiura

Auto-generated profile, based on publicly available information

Isamu Sugiura

Division of Hematology and Oncology, Toyohashi Municipal Hospital, Toyohashi, Japan

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2020 in Blood Advances
Verified
Journal Article
Open access
PDF file
YIYuichi Ishikawa
Yuichi Ishikawa
NKNaomi Kawashima
Naomi Kawashima
YAYoshiko Atsuta
Yoshiko Atsuta
ISIsamu Sugiura
Isamu Sugiura
MSMasashi Sawa
Masashi Sawa
HKHitoshi Kiyoi
Hitoshi Kiyoi
Key Points: KIT exon 17 mutation is a poor prognostic factor in AML patients with RUNX1-RUNX1T1, but not in those with CBFB-MYH11. NRAS mutation is a poor prognostic factor in AML patients with CBFB-MYH11.

21 January 2022 in Blood Advances
Verified
Journal Article
Open access
PDF file
ISIsamu Sugiura
Isamu Sugiura
NDNoriko Doki
Noriko Doki
THTomoko Hata
Tomoko Hata
RCRyuko Cho
Ryuko Cho
TIToshiro Ito
Toshiro Ito
YMYasushi Miyazaki
Yasushi Miyazaki
The standard treatment for adults with Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL) in Japan is imatinib-based chemotherapy followed by allogeneic hematopoietic stem cell transplantation (HSCT). However, ∼40% of patients cannot undergo HSCT in their first complete remission (CR1) because of chemotherapy-related toxicities or relapse before HSCT or older age. In this study, we evaluated dasatinib-based 2-step induction with the primary end point of 3-year event-free survival (EFS). The first induction (IND1) was dasatinib plus prednisolone to achieve CR, and IND2 was dasatinib plus intensive chemotherapy to achieve minimal residual disease (MRD) negativity. For patients who achieved CR and had an appropriate donor, HSCT during a consolidation phase later than the first consolidation, which included high-dose methotrexate, was recommended. Patients with pretransplantation MRD positivity were assigned to receive prophylactic dasatinib after HSCT. All 78 eligible patients achieved CR or incomplete CR after IND1, and 52.6% achieved MRD negativity after IND2. Nonrelapse mortality (NRM) was not reported. T315I mutation was detected in all 4 hematological relapses before HSCT. Fifty-eight patients (74.4%) underwent HSCT in CR1, and 44 (75.9%) had negative pretransplantation MRD. At a median follow-up of 4.0 years, 3-year EFS and overall survival were 66.2% (95% confidence interval [CI], 54.4-75.5) and 80.5% (95% CI, 69.7-87.7), respectively. The cumulative incidence of relapse and NRM at 3 years from enrollment were 26.1% and 7.8%, respectively. Dasatinib-based 2-step induction was demonstrated to improve 3-year EFS in Ph+ ALL. This study was registered in the UMIN Clinical Trial Registry as #UMIN000012173.

29 October 2019 in International Journal of Hematology
Verified
Journal Article
Closed access
PDF file
ISIsamu Sugiura
Isamu Sugiura
KSKenshi Suzuki
Kenshi Suzuki
MRMasaki Ri
Masaki Ri
TCTakaaki Chou
Takaaki Chou
NTNaoki Takezako
Naoki Takezako
SIShinsuke Iida
Shinsuke Iida

1 April 2010
Verified
Journal Article
Closed access
CSChihiro Shimazaki
Chihiro Shimazaki
HMHirokazu Murakami
Hirokazu Murakami
MSMorio Sawamura
Morio Sawamura
MMMasayuki Matsuda
Masayuki Matsuda
TKTomohiro Kinoshita
Tomohiro Kinoshita
KSKazuyuki Shimizu
Kazuyuki Shimizu